Healthcare and wellness investment firm NDude Labs has announced a strategic growth investment in Nutriventia, an Indian nutraceutical ingredients company, to support its international expansion and strengthen its research and development capabilities.
The investment will be used to deepen Nutriventia’s clinical R&D pipeline, expand its branded ingredient portfolio and proprietary delivery technology, and establish a dedicated commercial team in the United States.
Nutriventia develops clinically validated, branded nutraceutical ingredients designed to address health and wellness needs. Its portfolio includes TurmXTRA, a low-dose turmeric ingredient for joint and musculoskeletal health; CaffXtend, a natural caffeine-based mental alertness ingredient; Melotime, a sustained-release melatonin ingredient; Ashwanova (Prolanza), a root-only Ashwagandha ingredient; and C-Fence, a long-acting vitamin C formulation. The company is also preparing to launch ALAXTRA, an alpha lipoic acid ingredient.
Nitin Thakor, Managing Director, NDude Labs, said the investment reflects the firm’s focus on backing science-led businesses built in India with the potential to expand globally.
“NDude Labs can help accelerate that growth through its cross-border expertise and the Dude Operating System (DOS), our AI-native operating system,” Thakor said.
Nutriventia’s ingredients are currently supplied to formulators and wellness brands across the United States, Europe, Australia, South Korea and Japan.
The company said the investment comes as international wellness brands increasingly seek clinically validated and evidence-backed ingredients rather than commodity-based products.
Rajat Mittal Shah, Co-Founder and Executive Director, Nutriventia, said the partnership would enable the company to expand its clinical pipeline and delivery platforms while maintaining its focus on scientific research.
Vishal Shah, Co-Founder and Managing Director, Nutriventia, said the investment would support the expansion of commercial infrastructure across key international markets.
According to MarketsandMarkets, the global nutraceutical ingredients market is projected to grow from $108.33 billion in 2026 to $161.53 billion by 2031.
Investec advised Nutriventia on the transaction. Cyril Amarchand Mangaldas and Stratage Law Partners provided legal counsel, while PwC acted as the due diligence advisor.
